Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40EV7 | ISIN: US2283394045 | Ticker-Symbol:
NASDAQ
15.01.25
19:15 Uhr
0,076 US-Dollar
-0,012
-13,32 %
1-Jahres-Chart
CROWN ELECTROKINETICS CORP Chart 1 Jahr
5-Tage-Chart
CROWN ELECTROKINETICS CORP 5-Tage-Chart
GlobeNewswire (Europe)
48 Leser
Artikel bewerten:
(0)

Crown Electrokinetics Corp.: Crown Strengthens Financial Foundation for Growth and Profitability in 2025

Finanznachrichten News

Current Cash Position Exceeding $25 Million or Approximately $0.11 Per Share

2025 Revenue Guidance of $30 Million to $35 Million

On Track to Achieve Profitability in First Half of 2025

LOS ANGELES, Jan. 15, 2025 (GLOBE NEWSWIRE) -- - Crown Electrokinetics Corp. (NASDAQ: CRKN) ("Crown" or the "Company"), a leading provider of innovative technology infrastructure solutions that benefit communities and the environment, today announced it has significantly strengthened its financial foundation, ensuring continued growth and expected profitability in 2025. With no debt and a cash balance exceeding $25 million, or approximately $0.11 per share, Crown is positioned for success in the year ahead, as reflected in its 2025 revenue guidance of $30 to $35 million.

"We recognize that 2024 was a challenging year for our shareholders, despite the considerable fundamental progress achieved in our underlying business," said Doug Croxall, CEO and Chairman, Crown. "The company you originally invested in has undergone a remarkable transformation, and we are committed to building on this strong foundation. Getting here unfortunately took a considerable amount of costly growth capital as we navigated the difficult realities of being a small public company trying to reach cashflow breakeven in a highly unfavorable financing climate. The fact that we are here today, with tremendous opportunities ahead, is a testament to our dedicated team, now 60 people strong."

"For the first time since our original IPO, we are fully capitalized and strategically positioned to evaluate and execute opportunities across all three of our diverse business divisions. From lead pipe identification and remediation to addressing global water scarcity with innovative technology infrastructure solutions, Crown is at the forefront of creating impactful change. Most importantly, 2025 is expected to mark a pivotal year as our Smart Window Inserts are installed in select U.S. commercial buildings as part of our highly anticipated strategic rollout," added Mr. Croxall.

"With all the pieces finally in place, we are eager to build on our progress and focus on delivering meaningful value for our shareholders by investing in growth opportunities aligned with our mission to innovate for a better future. With our strengthened financial position and no immediate plans or need to raise additional capital, Crown is well positioned to continue leading the way with transformative solutions that benefit both communities and the environment," concluded Mr. Croxall.

In addition, Crown has filed a $500 million Form S-3 registration statement with the Securities and Exchange Commission ("SEC") to replace its expiring shelf registration. This proactive filing ensures Crown retains both the flexibility and optionality to raise capital in the future, supporting growth initiatives, strategic investments, and operational needs as opportunities arise.

About Crown
Crown (Nasdaq: CRKN) is an innovative infrastructure solutions provider dedicated to benefiting communities and the environment. Comprised of three business divisions, Smart Windows, Fiber Optics, and Water Solutions, Crown is developing and delivering cutting edge solutions that are challenging the status quo and redefining industry standards. For more information, please visit www.crownek.com.

Forward Looking Statements
Certain statements in this news release may be "forward-looking statements" (within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995) regarding future events or Crown's future financial performance that involve certain contingencies and uncertainties, including those discussed in Crown's Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent reports Crown files with the U.S. Securities and Exchange Commission from time to time, in the sections entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations". Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Crown Electrokinetic Corporation undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

For more information, please contact:

Investor Relations
ir@crownek.com

Public Relations
pr@crownek.com


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.